Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 1, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of August 31, 2016:
- Total Issued Ordinary Shares: 5,367,036,144 (25p each)
- Treasury Shares: 491,505,950
- Total Voting Rights: 4,875,530,194
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital figures for shareholder notification purposes.
Investor Verification Checklist
- Verify the total number of voting rights (4,875,530,194) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,505,950) to calculate the correct denominator for ownership percentage calculations.
- Note that this filing does not contain financial results; refer to the Company's Form 20-F or interim reports for performance metrics.